Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (ECZTRA 1)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Sponsor: LEO Pharma
Listed as NCT03131648, this PHASE3 trial focuses on Atopic Dermatitis and remains completed. Sponsored by LEO Pharma, it has been updated 22 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE3
▶ Show 17 earlier versions
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Mar 2023 [monthly]
Completed PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Dec 2019 — Dec 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE3
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- LEO Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States , Arlington Heights, United States , Asahikawa, Japan , Augsburg, Germany , Austin, United States , Badalona, Spain , Barcelona, Spain , Berlin, Germany , Bexley, United States , Bielefeld, Germany and 90 more locations